Brief: Upon Termination Of Deal Mirati Therapeutics Will Be Required To Pay Bristol-Myers Squibb Termination Fee
10/10/2023 12:52
Oct 10 (Reuters) - Bristol-Myers Squibb Co BMY.N :
* MIRATI THERAPEUTICS INC- UPON TERMINATION OF DEAL CO WILL
BE
REQUIRED TO PAY BRISTOL-MYERS SQUIBB TERMINATION FEE OF $168
MILLION
* MIRATI THERAPEUTICS INC - BRISTOL-MYERS SQUIBB WILL BE
REQUIRED
TO PAY CO REVERSE TERMINATION FEE OF $240 MILLION UNDER CERTAIN
SPECIFIED CIRCUMSTANCES
Source text for Eikon: ID:
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)